Navigation Links
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
Date:7/11/2014

psy." said Douglas Reynolds, President, Sunovion Pharmaceuticals Canada Inc.."Adequate seizure control remains an unmet medical need for a significant number of patients and Sunovion is committed to providing a treatment option to address this need."

About Partial-Onset Seizures
Epilepsy is a chronic neurological condition characterized by recurrent seizures resulting from abnormal firing of impulses from nerve cells in the brain2. In partial-onset seizures, these bursts of electrical activity are initially focused in specific areas of the brain, but may become more widespread, with symptoms varying according to the affected areas3,4.

About APTIOMTM
APTIOMTM, a voltage-gated sodium channel inhibitor, is a prescription medicine approved for use as adjunctive treatment of partial-onset seizures. Treatment with APTIOMTM should be initiated at 400 mg once daily. After one week, dosage may be increased to the recommended maintenance dosage of 800 mg once daily. Some patients may benefit from the maximum recommended maintenance dosage of 1,200 mg once daily, although this dosage is associated with an increase in adverse reactions. The maximum dose of 1,200 mg daily should only be initiated after the patient has tolerated 800 mg daily for at least a week. For some patients, treatment may be initiated at 800 mg once daily if the need for additional seizure reduction outweighs an increased risk of adverse reactions during initiation.  The initial research and development of eslicarbazepine acetate was performed by BIAL, a privately held Portuguese research-based pharmaceutical company. Subsequently, Sunovion acquired the rights under an exclusive license to further develop and commercialize eslicarbazepine acetate in the U.S. and Canadian markets from BIAL. Eslicarbazepine acetate was approved on November 8, 2013, by the U.S. FDA as adjunctive treatment of partial-
'/>"/>

SOURCE Sunovion Pharmaceuticals Canada Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
2. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
3. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
4. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
5. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
6. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
7. Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
8. Avanir Pharmaceuticals to Participate in Two Conferences in December
9. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
10. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
11. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... ... technology are highlighted at leading industry events. , ... Washington, DC (PRWEB) June 11, 2010 -- Open source software will be ... DIA Annual Meeting is the premier event for professionals involved in the discovery, ...
... June 11 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ) ... products in China , today reported,its financial results for the ... , , 4Q10 Financial Highlights, ... year-over-year increase;, ...
... ... of the evolution of the influenza virus and its human host, post-graduate student Stephen Huff ... of safe, free software downloads - best of all, the service is free. , ... (PRWEB) June 5, 2010 -- We ...
Cached Biology Technology:Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 2Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 3China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 2China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 3China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 4China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 5China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 6China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 7China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 8China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 9China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 10China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 11China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 12China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 13China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 14China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 15China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010 16Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 2Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 3Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 4
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
... Director of Genomic Technologies, Dr Yijun RUAN, led a ... how genes interact/communicate and influence each other, even when ... discovery is crucial in understanding how human genes work ... and coordination takes place in human cells. The ...
... Spotted salamanders exposed to contaminated roadside ponds are ... paper in Scientific Reports. This study provides the first ... negative effects of roads apparently by evolving rapidly. ... a host of contaminants from road runoff. Chief among ...
... The first study to check the effects of eating ... small helpings of purple potatoes (Purple Majesty) a day decreases ... In a report in the ACS, Journal of Agricultural ... seemingly small, is sufficient to potentially reduce the risk of ...
Cached Biology News:Singapore scientists lead in 3D mapping of human genome to help understand human diseases 2Road runoff spurring spotted salamander evolution 2
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... Microarray Gene Frame® has been specifically ... frames feature the same dual strength ... Frame® range for easy removal after ... and there are three sizes available. ...
For microscopy...
... slide processing offering reproducibility, reliability and ... miniaturization, automation and massive parallel analysis ... with many applications in both industrial ... from gene expression profiling, gene regulation ...
Biology Products: